Tricida: Funding, Investors & Team (Sep 2026)
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
Tricida has raised $167M across 2 funding rounds on record, the most recent a Post-IPO Debt of $125M announced in Oct 2022.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Tricida Company Profile and Key Stats
Latest funding round on record: Oct 2022.
Tricida Funding Rounds
Tricida raised $42.0M in a Post-IPO Equity announced in Nov 2021.
11 months later, a Post-IPO Debt of $125M was announced in Oct 2022.
Tricida Founders and Leadership Team
Contact details for the Tricida team: 1 of 1 has an email address on file.
Start 14-day free trial →Tricida Funding Compared to Other Health Care Startups
Tricida's latest round of $125M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tricida in Health Care and Menlo Park
Companies Similar to Tricida
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Tricida Funding FAQs
What does Tricida do?
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
How much funding has Tricida raised?
Tricida has raised $167M across 2 rounds on record. The most recent is a Post-IPO Debt of $125M announced in Oct 2022.
When did Tricida last raise funding?
Tricida's most recent funding round on record is a Post-IPO Debt of $125M, announced in Oct 2022.
Who is the CEO of Tricida?
Gerrit Klaerner is listed as CEO at Tricida.
Where is Tricida headquartered?
Tricida is based in Menlo Park, California, United States.
How many employees does Tricida have?
Tricida is in the 51-100 employee band.
How does Tricida's funding compare to other Health Care startups?
Tricida's latest round of $125M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Tricida Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tricida is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.